HRTX

HTX-019-202 - CINVANTI® (aprepitant) | GUARDS-1

COVID-19

Phase 2

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

TITLE:  HTX-019-202 - CINVANTI® (aprepitant) Treatment in COVID-19

  • ClinicalTrial.gov (NCT04470622): Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)


WHAT IS THE CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA/EVENTS

PRESS RELEASE

MECHANISM OF ACTION / RATIONALE

  • Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors. Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced emesis.



Updated by HC

#HRTX, #HTX-019-202, #CINVANTI, #aprepitant, #GUARDS-1, #COVID, #COVID-19, #coronavirus

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Trilaciclib NDA Filing (GTHX)...

We are fans of GTHX and hope things go well. But we are worried if NDA for Trilaciclib in NSCLC is accepted and accelerated date is set, that expedited PDUFA is too rushed for FDA during a pandemic. S...

HRTX CRL for HTX-011...

Heron Therapeutics received a Complete Response Letter from the U.S. FDA for the NDA for HTX-011 which is used for post-operative pain. The FDA stated that the CRL was given out because of a need for ...

HRTX - bear or bull? Our take ...

Heron has an upcoming PDUFA date for its longer acting post-op pain medicine, HTX-011. This is the second time around for HTX-011 as the first time unfortunately resulted in a CRL. See our article (HE...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon